<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>aaspjournal</PublisherName>
      <JournalTitle>Journal of Asian Association of Schools of Pharmacy</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 13 Issue 1</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>January - December 2024</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Pharmacy</ArticleType>
      <ArticleTitle>PIK3CA gene mutation induced rare vascular diseases</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>12</FirstPage>
      <LastPage>19</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Meng</FirstName>
          <LastName>Gu</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Xuanzhe</FirstName>
          <LastName>Zhu</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Yi Zhun</FirstName>
          <LastName>Zhu*</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI>https://doi.org/10.62100/jaasp.2024.13103 </DOI>
      <Abstract>The PIK3CA gene is the member of PI3K family. Although targeting the mutation of PIK3CA is a good treatment strategy for cancer, various other reasons can also worsen the cancer’s progression and lead to the death of patients. However, PIK3CA can be treated as the main target that leads to the rare vascular diseases’ progression. Therefore, this review will focus on the mutation of the PIK3CA gene in rare vascular diseases, including singletype vascular malformation and multiple-type combined vascular malformation. The specific mechanisms, treatment strategies of PIK3CA, and limitations of the current treatment methods for these rare vascular diseases will also be discussed in this review. Moreover, some rare conditions for the patients with rare vascular diseases will be discussed in this review.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>PIK3CA gene mutation, rare vascular diseases, vascular malformation, surgical and drug therapies</Keywords>
      <URLs>
        <Abstract>https://aaspjournal.org/ubijournal-v1copy/journals/abstract.php?article_id=15337&amp;title=PIK3CA gene mutation induced rare vascular diseases</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>